HLA-C and neoplasm: Thus, unlike CARs, TCRs provide T cells the ability to recognize peptide:MHC complexes not only on the tumor cells, but also on antigen presenting cells such as cDC1s, which may be a particular advantage of TCR based approach over CAR-based engineering strategies (53, 114).